Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease

被引:3
作者
Liu, Tso-Tsai [1 ,2 ]
Qiu, He [3 ]
Liu, Shi-Yu [4 ]
Chien, Chieh [2 ,5 ]
Wang, Jen-Hung [6 ]
Wong, Ming-Wun [1 ,2 ,7 ]
Yi, Chih-Hsun [1 ,2 ]
Lin, Lin [1 ,2 ]
Lei, Wei-Yi [1 ,2 ]
Liang, Shu-Wei [1 ,2 ]
Hung, Jui-Sheng [1 ,2 ]
Huang, Jee-Fu [8 ]
Chen, Chien-Lin [1 ,2 ,9 ]
Han, Ma Ai Thanda [3 ,10 ]
机构
[1] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med, Hualien, Taiwan
[2] Tzu Chi Univ, Hualien, Taiwan
[3] Rutgers New Jersey Med Sch, Dept Med, Div Gastroenterol & Hepatol, Newark, NJ USA
[4] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Nutr, Hualien, Taiwan
[5] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Rehabil Med, Hualien, Taiwan
[6] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med Res, Hualien, Taiwan
[7] Tzu Chi Univ, Sch Postbaccalaureate Chinese Med, Hualien, Taiwan
[8] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
[9] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan
[10] Univ Arizona, Banner Univ Med Ctr, Dept Med, Div Gastroenterol & Hepatol, 1441 N 12th St,Rm 1080, Phoenix, AZ 85006 USA
关键词
fatty liver; lifestyle intervention; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; weight loss; CONTROLLED ATTENUATION PARAMETER; NONINVASIVE DIAGNOSIS; WEIGHT-LOSS; FIBROSIS; BIOPSY; VARIABILITY; CAP;
D O I
10.1002/kjm2.12580
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Metabolic-associated fatty liver disease (MAFLD) is a growing global problem associated with increasing obesity prevalence. Lifestyle modifications are currently recommended, including weight reduction, exercise, and diet control. This study evaluated the short-term effect of lifestyle modifications on transient elastography (TE) values in an obese population with MAFLD. Thirty-two MAFLD patients were recruited for this prospective study and all subjects participated in a 3-month program of lifestyle modification. Sequential demographic parameters and biochemical tests were compared before and after program completion. Liver fat and fibrosis changes were measured using TE with controlled attenuated parameter (CAP) and liver stiffness measurements (LSM). The mean age was 38.7 years old (10 males). The body weight (88.09 kg vs. 80.35 kg), body mass index (32.24 kg/m(2) vs. 29.4 kg/m(2)), waist (103.19 cm vs. 95.75 cm), and hip circumference (111.67 cm vs. 104.75 cm), and blood pressure (128/78 mmHg vs. 119/71 mmHg) significantly improved before and after the intervention, respectively. Aspartate aminotransaminase (24.06 U/L vs. 18.91 U/L), alanine aminotransaminase (33 U/L vs. 23.72 U/L), creatinine (0.75 mg/dl vs. 0.70 mg/dl), cholesterol (176.41 mg/dl vs. 166.22 m/dl), gamma-glutamyl transferase (26.59 IU/L vs. 19.81 IU/L), and low-density lipoprotein cholesterol (115.63 mg/dl vs. 103.19 mg/dl) also improved after the 3-month intervention. The average CAP significantly decreased after intervention (297.5 dB/m vs. 255.0 dB/m), however, no significant difference in LSM was observed (5.24 kPa vs. 4.82 kPa). The current study suggests that short-term lifestyle modification can effectively improve hepatic steatosis, and TE may serve as a monitoring tool for therapeutic intervention.
引用
收藏
页码:1012 / 1019
页数:8
相关论文
共 50 条
[21]   Editorial: Exercise, diabetes and metabolic-associated fatty liver disease [J].
Sun, Yang ;
Sun, Chao ;
Hu, Gang ;
Shen, Yun .
FRONTIERS IN ENDOCRINOLOGY, 2023, 14
[22]   Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action [J].
Benlloch, Salvador ;
Moncho, Francesc ;
Gorriz, Jose Luis .
NEFROLOGIA, 2024, 44 (02) :129-138
[23]   Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name [J].
Ng, Cheng Han ;
Huang, Daniel Q. ;
Nguyen, Mindie H. .
CLINICAL AND MOLECULAR HEPATOLOGY, 2022, 28 (04) :790-801
[24]   Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review [J].
Jakielska, Ewelina ;
Gluszak, Pawel ;
Walczak, Marta ;
Bryl, Wieslaw .
GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2023, 18 (02) :148-153
[25]   Metabolic-associated fatty liver disease: New nomenclature and approach with hot debate [J].
Fouad, Yasser .
WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (02) :123-128
[26]   The Interlink Between Metabolic-Associated Fatty Liver Disease and Polycystic Ovary Syndrome [J].
Vidal-Cevallos, Paulina ;
Mijangos-Trejo, Alejandra ;
Uribe, Misael ;
Tapia, Norberto Chavez .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) :533-545
[27]   The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study [J].
Yilmaz, Yusuf ;
Yilmaz, Nimet ;
Ates, Fehmi ;
Karakaya, Fatih ;
Gokcan, Hale ;
Kaya, Eda ;
Adali, Gupse ;
Kartal, Aysun Caliskan ;
Sen, Ilker ;
Ahishali, Emel ;
Ozenirler, Seren ;
Koruk, Mehmet ;
Uygun, Ahmet ;
Idilman, Ramazan .
HEPATOLOGY FORUM, 2021, 2 (02) :37-42
[28]   Mechanisms of Action of Mesenchymal Stem Cells in Metabolic-Associated Fatty Liver Disease [J].
Yi, Sitong ;
Cong, Qingwei ;
Zhu, Ying ;
Xu, Qiumin .
STEM CELLS INTERNATIONAL, 2023, 2023
[29]   From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? [J].
Kang, Seong Hee ;
Cho, Yuri ;
Jeong, Soung Won ;
Kim, Seung Up ;
Lee, Jin-Woo .
CLINICAL AND MOLECULAR HEPATOLOGY, 2021, 27 (02) :257-269
[30]   Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center [J].
Laursen, Tea Lund ;
Kjaer, Mikkel Breinholt ;
Kristensen, Louise ;
Gronbaek, Henning .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)